Results 181 to 190 of about 33,833 (238)

Evaluation of clofazimine-bedaquiline combination as a candidate regimen for macrolide-resistant <i>Mycobacterium avium</i> complex infection. [PDF]

Antimicrob Agents Chemother
Park J, Choi S, Jeon YR, Kim L-H, Lee JM, Shin SJ.   +5 more
europepmc   +1 more source

Corrigendum to "Model-Informed Once-Daily Dosing Strategy for Bedaquiline and Delamanid in Children, Adolescents and Adults with Tuberculosis". [PDF]

Clin Pharmacol Ther
europepmc   +1 more source

Drug Resistance and Comorbidities in the Treatment of Pulmonary Tuberculosis: A Multicenter Retrospective Cohort Study. [PDF]

Antibiotics (Basel)
Osipov NN, Spelnikov D, Belyaeva E, Kulpina A, Nazarenko M, Mikhail G, Nikolenko NY, Kudlay D, Starshinova A.   +8 more
europepmc   +1 more source

High-dose amikacin in the first week of all-oral rifampicin-resistant TB treatment is safe: a single-arm trial. [PDF]

IJTLD Open
Snobre J, Gasana J, Decroo T, Mucyo Y, Jacobs BKM, Rigouts L, Martin IC, Herssens N, Hakizayezu F, Ntihumbya JB, Kilibazayire A, de Viron E, Runyambo D, Ndayishimiye C, Merle CS, Muvunyi CM, Migambi P, Sturkenboom MGG, de Jong BC, Ngabonziza JCS.   +19 more
europepmc   +1 more source

Bedaquiline and levofloxacin replacing rifampicin for the treatment of TB. [PDF]

IJTLD Open
Chiang CY, Bai KJ, Yu MC.
europepmc   +1 more source

The Effectiveness and Safety of Bedaquiline, Pretomanid, and Linezolid (BPaL)-Based Regimens for Rifampicin-Resistant Tuberculosis in Non-Trial Settings-A Prospective Cohort Study in Belarus and Uzbekistan. [PDF]

Clin Infect Dis
Sinha A, Klebe R, Rekart ML, Alvarez JL, Skrahina A, Yatskevich N, Solodovnikova V, Viatushka D, Parpieva N, Safaev K, Liverko I, Tigay Z, Moe S, Khristusev A, Allamuratova S, Mirzabaev S, Achilov M, Samieva N, Lachenal N, Merle CS, Sall FB, Restrepo CG, Tan C, Sitali N, Saunders MJ.   +24 more
europepmc   +1 more source

A New Era in Tuberculosis Prevention and Treatment: Breakthroughs in Drug Development and Future Prospects. [PDF]

Infect Dis Ther
Zhao CY, Song C, Lu YB, Huang AC, Zeng CM, Liu RH, Li WW, Xie ZH, Zhu QD.   +8 more
europepmc   +1 more source

Impact of fluoroquinolone resistance on the cost-effectiveness of empiric treatment for multidrug- or rifampicin-resistant tuberculosis. [PDF]

PLOS Glob Public Health
Kim C, Sweeney S, Sohn H, Knight GM, McQuaid CF.   +4 more
europepmc   +1 more source